Holen Sie sich die Stockscreener-App
1.34
0.74%
-0.01
Handel nachbörslich:
1.38
0.04
+2.99%
Schlusskurs vom Vortag:
$1.35
Offen:
$1.25
24-Stunden-Volumen:
334.35K
Relative Volume:
0.87
Marktkapitalisierung:
$26.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.76M
KGV:
-1.0388
EPS:
-1.29
Netto-Cashflow:
-
1W Leistung:
+20.72%
1M Leistung:
+74.03%
6M Leistung:
-2.90%
1J Leistung:
+52.27%
1-Tages-Spanne:
$1.25
$1.455
1-Wochen-Bereich:
$1.05
$1.455
52-Wochen-Spanne:
$0.40
$2.33
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
NeuroSense Embarks on HIPAA Compliance Journey - TipRanks
NeuroSense Therapeutics Ltd: -52.36% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
NeuroSense Reports Positive Drug Study Results - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.9% - Defense World
It would be worthwhile to take a closer look at NeuroSense Therapeutics Ltd (NRSN) - US Post News
Lonza, NeuroSense Enter Alliance For ALS Candidate - Contract Pharma
NeuroSense Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
NeuroSense faces Nasdaq delisting over share price By Investing.com - Investing.com UK
NeuroSense faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification - PR Newswire
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification - StockTitan
Ratio Examination: NeuroSense Therapeutics Ltd (NRSN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
NeuroSense Therapeutics Ltd: Navigating Market Fluctuations with a 13.81M Market Cap - The InvestChronicle
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Sees Significant Decline in Short Interest - Defense World
NeuroSense Eyes Lucrative Pharma Partnerships for ALS Drug - TipRanks
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug - Yahoo Finance
NeuroSense Therapeutics Gains Nasdaq Extension - TipRanks
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences - GuruFocus.com
NeuroSense to Participate in Upcoming ALS Conferences: European - GuruFocus.com
NeuroSense Completes Dosing of Last Patient in the Double-Blind - GuruFocus.com
NeuroSense Therapeutics Announces Share Issuance - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading 5.7% Higher - Defense World
Neurosense Therapeutics Ltd expected to post a loss of 20 cents a shareEarnings Preview - XM
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price - The Malaysian Reserve
NeuroSense secures $600,000 in private placement - Investing.com
NeuroSense secures $600,000 in private placement By Investing.com - Investing.com Canada
Amyotrophic Lateral Sclerosis Pipeline 2024: Clinical Trials - openPR
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price - PR Newswire
NeuroSense Therapeutics Announces Strategic Securities Sale - TipRanks
Stock Market Recap: NeuroSense Therapeutics Ltd (NRSN) Concludes at 0.68, a -10.50 Surge/Decline - The Dwinnex
New biomarker data supports NeuroSense’s ALS drug - Yahoo Finance
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial - The Malaysian Reserve
NeuroSense Therapeutics Ltd (NRSN) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
NeuroSense reports positive ALS trial results, plans phase 3 By Investing.com - Investing.com Canada
Edgewise Therapeutics Inc Inc. (EWTX) Price Performance: The Role of Supply and Demand - The InvestChronicle
NRSN’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
NeuroSense reports positive ALS trial results, plans phase 3 - Investing.com
NeuroSense’s ALS Drug Shows Promise in Trial - TipRanks
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial - PR Newswire
NRG Energy Inc. (NRG) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial - StockTitan
AC Immune bags FDA fast track designation - European Biotechnology News
Amyotrophic Lateral Sclerosis Treatment Market size is set to grow by USD 663.7 million from 2024-2028, Increase in incidence and prevalence of amyotrophic lateral sclerosis to boost the market growth, Technavio - The Malaysian Reserve
Amyotrophic Lateral Sclerosis Treatment Market size is set to grow by USD 663.7 million from 2024-2028, Increase in incidence and prevalence of amyotrophic lateral sclerosis to boost the market growth, Technavio - PR Newswire
Amyotrophic Lateral Sclerosis Treatment Market size is set to grow by USD 663.7 million from 2024-2028, Increase in incidence and prevalence of amyotrophic lateral sclerosis to boost the market growth, Technavio - Yahoo Finance
How Are Things Looking For NeuroSense Therapeutics Ltd (NASDAQ: NRSN) For The Short Term? - Stocks Register
Stock Market Recap: NeuroSense Therapeutics Ltd (NRSN) Concludes at 0.73, a -3.75 Surge/Decline - The Dwinnex
NeuroSense Therapeutics Ltd’s Mixed Bag: Down -13.90% in 6 Months, Down -18.79% in 30 Days - The InvestChronicle
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 14.3% in June - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update - Defense World
NeuroSense Therapeutics Ltd (NRSN) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):